Furthermore, GLP-1 agonists have demonstrated a lower risk of hypoglycemic events compared to insulin, and some have even exhibited cardiovascular protective effects (11), As a result, GLP-1 agonists have emerged as a promising new class of drugs with significant growth potential in the treatment of diabetes. This evidence concerns the gene INS and diabetes mellitus.